Quan ML, Wong PC, Wang C, Woerner F, Smallheer JM, Barbera FA, Bozarth JM, Brown RL, Harpel MR, Luettgen JM, Morin PE, Peterson T, Ramamurthy V, Rendina AR, Rossi KA, Watson CA, Wei A, Zhang G, Seiffert D, Wexler RR J Med Chem. 2014 Feb 13;57(3):955-69. doi: 10.1021/jm401670x. Epub 2014 Jan 17.PMID:24405333 Abstract Antithrombotic […]
View Post antithrombotics, Factor XIa, FXIa, tetrahydroquinolineWong PC, Jiang X. Thromb Haemost. 2010 Aug;104(2):302-10. Epub 2010 Jun 29. Apixaban is an oral, direct and highly selective factor Xa (FXa) inhibitor in late-stage clinical development. This study evaluated the in vitro effect of apixaban on human platelet aggregation induced by thrombin derived via the extrinsic pathway. Direct inhibitors of FXa (rivaroxaban), FVIIa (BMS-593214), thrombin […]
View Post factor Xa, FXIaSchumacher WA, Luettgen JM, Quan ML, Seiffert DA. Arterioscler Thromb Vasc Biol. 2010 Mar;30(3):388-92. Epub 2010 Feb 5. The dose-limiting issue with available anticoagulant therapies is bleeding. Is there an approach that could provide antithrombotic protection with reduced bleeding? One hypothesis is that targeting proteases upstream from the common pathway provides a reduction in thrombin sufficient to impede occlusive […]
View Post antithrombotic, coagulation, FXIa, hemostasis, thrombin generation, thromboembolic, thromboembolism